CapsoVision, Inc.

CV Healthcare Medical Devices

CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 92.6% and free cash flow fell 84.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.53 0.08 +1.24%
Market cap
$343.2M
P/E
2.1×
Fwd P/E
−13.8×
Dividend yield
—
F-score
n/a
Altman Z
17.04
Beneish M
−3.47
Dividend safety
n/a
Dec '24 Dec '25
P/E ratio
0.00 0.00
Altman Z-Score
— 17.04
P/S ratio
0.67 19.37
Altman Z″-Score (non-manufacturers)
(29.09) (30.12)
P/FCF ratio
0.00 0.00
Beneish M-Score
— (3.47)
P/Operating CF
(1.77) (34.15)
P/B ratio
0.00 19.80
EV/Sales
0.58 18.62
EV/EBITDA
0.00 0.00
EV/FCF
(0.32) (11.00)
Current Ratio
8.24 3.77
Net Debt/EBITDA
0.48 0.41
Debt/Equity
0.00 0.00
ROE
0.00% 43.55%
ROA
0.00% (144.79%)
ROIC
0.00% (506.59%)
Return on Tangible Assets
(144.54%) (196.96%)
Average Days of Receivables
62.13 67.27
Earnings Yield
(282.26%) (9.65%)
Free Cash Flow Yield
(274.76%) (8.74%)
Free Cash Flow per Share
(10.02) (0.93)
Book value per Share
(64.11) 0.54
Free Cash Flow
(20.24) (22.95)
EV/EBIT
0.00 0.00
Other line items

Show all line items

Columns are period end dates